XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, open label, randomized phase II clinical study. The aim is to evaluate the
safety and efficacy of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) combined with XELOX
regimen in pMMR locally advanced rectal cancer during the perioperative period. Eligible
patients will receive either Cadonilimab plus XELOX or XELOX alone for 4 cycles before and 4
cycles after surgery. The primary endpoint is the pathological complete response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences